As advised via PHARMAC Tender Results of 31 May 2019 there is to be a change in the listing and future sole supply of Dexamethasone Phosphate Injection.

New listing from 1 February 2020

Dexamethasone Phosphate Panpharma Inj 4 mg per ml, 1 ml 10                              Pharmacode TBA                                    Schedule price $9.25

Dexamethasone Phosphate Panpharma Inj 4 mg per ml, 2 ml 10                              Pharmacode TBA                                    Schedule price $16.37

Incumbent brand

Dexamethasone Phosphate Max Health Inj 4 mg per ml, 1 ml 10                              Pharmacode 2451689                    Schedule price $14.19

Dexamethasone Phosphate Max Health Inj 4 mg per ml, 2 ml 10                              Pharmacode 2519143                    Schedule price $25.18

HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 July 2020.

Brand switch fee for Community Pharmacy not notified with tender results.

As of the date of this notification ProPharma / PWR cannot accept Dexamethasone Inj Max Health for credit under any circumstances.

From 1 July 2019 community pharmacies dispensing Dexamethasone Inj 4 mg per ml will need to support patients changing to the new brand and manage stock during the transition.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.

You MUST manage your stock to avoid being caught with stock at the time sole supply commences 1 July 2020. Failure to do so may prove very costly.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply 1 July 2020 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author

Close